Search by Drug Name or NDC
NDC 63323-0673-89 Palonosetron 0.25 mg/5mL Details
Palonosetron 0.25 mg/5mL
Palonosetron is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Fresenius Kabi USA, LLC. The primary component is PALONOSETRON HYDROCHLORIDE.
MedlinePlus Drug Summary
Palonosetron injection is used to prevent nausea and vomiting that may occur within 24 hours after receiving cancer chemotherapy or surgery. It is also used to prevent delayed nausea and vomiting that may occur several days after receiving certain chemotherapy medications. Palonosetron injection is in a class of medications called 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting.
Related Packages: 63323-0673-89Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Palonosetron Injection
Product Information
| NDC | 63323-0673 |
|---|---|
| Product ID | 63323-673_c1aa6a23-e1b5-441a-a947-55b35d33509b |
| Associated GPIs | 50250070102020 5025007010E520 |
| GCN Sequence Number | 052943 |
| GCN Sequence Number Description | palonosetron HCl VIAL 0.25MG/5ML INTRAVEN |
| HIC3 | H6J |
| HIC3 Description | ANTIEMETIC/ANTIVERTIGO AGENTS |
| GCN | 20228 |
| HICL Sequence Number | 025512 |
| HICL Sequence Number Description | PALONOSETRON HCL |
| Brand/Generic | Generic |
| Proprietary Name | Palonosetron |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Palonosetron |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 0.25 |
| Active Ingredient Units | mg/5mL |
| Substance Name | PALONOSETRON HYDROCHLORIDE |
| Labeler Name | Fresenius Kabi USA, LLC |
| Pharmaceutical Class | Serotonin 3 Receptor Antagonists [MoA], Serotonin-3 Receptor Antagonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA206801 |
| Listing Certified Through | 2024-12-31 |
Package
Package Images
NDC 63323-0673-89 (63323067389)
| NDC Package Code | 63323-673-89 |
|---|---|
| Billing NDC | 63323067389 |
| Package | 10 SYRINGE, PLASTIC in 1 CARTON (63323-673-89) / 5 mL in 1 SYRINGE, PLASTIC (63323-673-21) |
| Marketing Start Date | 2018-09-19 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |
Standard Product Labeling (SPL)/Prescribing Information SPL b93fae8e-2b76-421e-95bc-ba08c211a7ea Details
HIGHLIGHTS OF PRESCRIBING INFORMATION
PALONOSETRON HYDROCHLORIDE Injection, for intravenous use
Initial U.S. Approval: 2003
INDICATIONS AND USAGE
Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT3) receptor antagonist indicated in:
Adults for prevention of:
- acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). (1)
- acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). (1)
Pediatric patients aged 1 month to less than 17 years for prevention of:
- acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). (1)
DOSAGE AND ADMINISTRATION
Chemotherapy-Induced Nausea and Vomiting (2.1)
|
*Note different dosing units in pediatrics |
||
| Age | Dose* | Infusion Time |
| Adults | 0.25 mg as a single dose | Infuse over 30 seconds beginning approximately 30 minutes before the start of chemotherapy |
| Pediatrics (1 month to less than 17 years) | 20 micrograms per
kilogram (maximum 1.5 mg) as a single dose | Infuse over 15 minutes beginning approximately 30 minutes before the start of chemotherapy |
Instructions for Intravenous Administration
- For a dose of 0.25 mg, use the entire contents (5 mL) of the prefilled syringe. Do not use the prefilled syringe to administer a dose of less than 0.25 mg (5 mL). (2.2)
DOSAGE FORMS AND STRENGTHS
0.25 mg (free base) per 5 mL (concentration: 0.05 mg per mL, 50 mcg per mL) single-dose prefilled syringe (3)
CONTRAINDICATIONS
Hypersensitivity to palonosetron or any of its components (4)
WARNINGS AND PRECAUTIONS
- Hypersensitivity reactions, including anaphylaxis and anaphylactic shock: reported in patients with or without known hypersensitivity to other selective 5-HT3 receptor antagonists. If symptoms occur, discontinue Palonosetron Hydrochloride Injection and initiate appropriate medical treatment. (5.1)
- Serotonin syndrome: reported with 5-HT3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (5.2, 7.1)
ADVERSE REACTIONS
Most common adverse reactions in
- chemotherapy-induced nausea and vomiting in adults (≥5%) are: headache and constipation (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
Serotonergic Drugs: Monitor for serotonin syndrome; if symptoms occur, discontinue Palonosetron Hydrochloride Injection and initiate supportive treatment. (7.1)
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 9/2020
Table Of Contents
FULL PRESCRIBING INFORMATION: CONTENTS*
1. INDICATIONS AND USAGE
2. DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
2.2 Instructions for Intravenous Administration
3. DOSAGE FORM AND STRENGTHS
4. CONTRAINDICATIONS
5. WARNINGS AND PRECAUTIONS
5.1 Hypersensitivity Reactions
5.2 Serotonin Syndrome
6. ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience
7. DRUG INTERACTIONS
7.1 Serotonergic Drugs
8. USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.4 Pediatric Use
8.5 Geriatric Use
10. OVERDOSAGE
11. DESCRIPTION
12. CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13. NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14. CLINICAL STUDIES
14.1 Prevention of Nausea and Vomiting Associated with MEC and HEC in Adults
14.2 Prevention of Nausea and Vomiting Associated with Emetogenic Chemotherapy, Including HEC in Pediatric Patients
16. HOW SUPPLIED/STORAGE AND HANDLING
17. PATIENT COUNSELING INFORMATION
- *
- Sections or subsections omitted from the full prescribing information are not listed.
1. INDICATIONS AND USAGE
Palonosetron Hydrochloride Injection is indicated in adults for prevention of:
- acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
- acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC).
Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of:
- acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.
2. DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
Prevention of Chemotherapy-Induced Nausea and Vomiting
The recommended dosage of Palonosetron Hydrochloride Injection for prevention of nausea and vomiting associated with HEC and MEC in adults and associated with emetogenic chemotherapy, including HEC in pediatric patients 1 month to less than 17 years of age is shown in Table 1.
|
*Note different dosing units in pediatrics |
||
| Age | Dose* | Infusion Time |
| Adults | 0.25 mg as a single dose | Infuse over 30 seconds beginning approximately 30 minutes before the start of chemotherapy |
| Pediatrics (1 month to less than 17 years) | 20 micrograms per kilogram (max 1.5 mg) as a single dose | Infuse over 15 minutes beginning approximately 30 minutes before the start of chemotherapy |
2.2 Instructions for Intravenous Administration
- Palonosetron Hydrochloride Injection is supplied ready for intravenous administration at a concentration of 0.05 mg/mL (50 mcg/mL).
- Do not mix Palonosetron Hydrochloride Injection with other drugs.
- Flush the infusion line with normal saline before and after administration of Palonosetron Hydrochloride Injection.
- Inspect Palonosetron Hydrochloride Injection visually for particulate matter and discoloration before administration.
- Expel air from syringe prior to administration. For a dose of 0.25 mg, use the entire contents (5mL) of the prefilled syringe.
- Do not use the prefilled syringe to administer a dose less than 0.25mg (5mL)
- Use aseptic technique while handling the syringe
3. DOSAGE FORM AND STRENGTHS
4. CONTRAINDICATIONS
Palonosetron Hydrochloride Injection is contraindicated in patients known to have hypersensitivity to palonosetron [see Warnings and Precautions (5.1)].
5. WARNINGS AND PRECAUTIONS
5.1 Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported with administration of Palonosetron Hydrochloride Injection [see Adverse Reactions (6.2)]. These reactions occurred in patients with or without known hypersensitivity to other 5-HT3 receptor antagonists. If hypersensitivity reactions occur, discontinue Palonosetron Hydrochloride Injection and initiate appropriate medical treatment. Do not reinitiate Palonosetron Hydrochloride Injection in patients who have previously experienced symptoms of hypersensitivity [see Contraindications (4)].
5.2 Serotonin Syndrome
The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of another 5-HT3 receptor antagonist alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia care unit or an infusion center.
Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g. agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Palonosetron Hydrochloride Injection and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue Palonosetron Hydrochloride Injection and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if Palonosetron Hydrochloride Injection is used concomitantly with other serotonergic drugs [see Drug Interactions (7.1)].
6. ADVERSE REACTIONS
Serious or otherwise clinically significant adverse reactions reported in other sections of labeling:
- Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
- Serotonin Syndrome [see Warnings and Precautions (5.2)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Chemotherapy-Induced Nausea and Vomiting
Adults
In double-blind randomized clinical trials for the prevention of nausea and vomiting induced by MEC or HEC, 1,374 adult patients received a single dose of Palonosetron Hydrochloride Injection, ondansetron (Studies 1 and 3) or dolasetron (Study 2) administered 30 minutes prior to chemotherapy [see Clinical Studies (14.1)].
Adverse reactions were similar in frequency and severity in all 3 treatment groups. Common adverse reactions reported in at least 2% of patients in these trials are shown in Table 2.
|
* Reported in at least 2% of patients in any treatment group |
|||
|
Adverse Reaction | Palonosetron Hydrochloride Injection 0.25 mg intravenously (N=633) | Ondansetron 32 mg intravenously (N=410) | Dolasetron 100 mg intravenously (N=194) |
| Headache | 9% | 8% | 16% |
| Constipation | 5% | 2% | 6% |
| Diarrhea | 1% | 2% | 2% |
| Dizziness | 1% | 2% | 2% |
| Fatigue | < 1% | 1% | 2% |
| Abdominal Pain | < 1% | < 1% | 2% |
| Insomnia | < 1% | 1% | 2% |
Less common adverse reactions, reported in 1% or less of patients, in Studies 1, 2 and 3 were:
- Cardiovascular: non-sustained tachycardia, bradycardia, hypotension, hypertension, myocardial ischemia, extrasystoles, sinus tachycardia, sinus arrhythmia, supraventricular extrasystoles and QT prolongation.
- Dermatological: allergic dermatitis, rash
- Hearing and Vision: motion sickness, tinnitus, eye irritation and amblyopia
- Gastrointestinal System: diarrhea, dyspepsia, abdominal pain, dry mouth, hiccups and flatulence
- General: weakness, fatigue, fever, hot flash, flu-like syndrome
- Liver: transient, asymptomatic increases in AST and/or ALT and bilirubin. These changes occurred predominantly in patients receiving highly emetogenic chemotherapy
- Metabolic: hyperkalemia, electrolyte fluctuations, hyperglycemia, metabolic acidosis, glycosuria, appetite decrease, anorexia
- Musculoskeletal: arthralgia
- Nervous System: dizziness, somnolence, insomnia, hypersomnia, paresthesia
- Psychiatric: anxiety, euphoric mood
- Urinary System: urinary retention
- Vascular: vein discoloration, vein distention
In other studies, 2 subjects experienced severe constipation following a single Palonosetron Hydrochloride Injection dose of approximately 0.75 mg (three times the recommended dose).
Pediatrics Aged 2 Months to 17 Years
In a pediatric clinical trial, 163 pediatric cancer patients with a mean age of 8 years received a single 20 mcg/kg (maximum 1.5 mg) intravenous infusion of Palonosetron Hydrochloride Injection 30 minutes before beginning the first cycle of emetogenic chemotherapy [see Clinical Studies (14.2)]. Adverse reactions were evaluated in pediatric patients receiving Palonosetron Hydrochloride Injection for up to 4 chemotherapy cycles. The following adverse reactions were reported in less than 1% of patients:
- Nervous System: headache, dizziness, dyskinesia.
- General: infusion site pain.
- Dermatological: allergic dermatitis, skin disorder.
6.2 Postmarketing Experience
The following adverse reactions have been identified during postapproval use of palonosetron HCl. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Hypersensitivity reactions: including dyspnea, bronchospasm, swelling/edema, erythema, pruritus, rash, urticaria, anaphylaxis and anaphylactic shock [see Warnings and Precautions (5.1)]
- Injection site reactions: including burning, induration, discomfort and pain
7. DRUG INTERACTIONS
7.1 Serotonergic Drugs
Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs). Monitor for the emergence of serotonin syndrome. If symptoms occur, discontinue Palonosetron Hydrochloride Injection and initiate supportive treatment [see Warnings and Precautions (5.2)].
8. USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
There are no available data on palonosetron HCl use in pregnant women to inform a drug-associated risk.
In animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral palonosetron HCl during the period of organogenesis at doses up to 1,894 and 3,789 times the recommended human intravenous dose in rats and rabbits, respectively (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data
Animal Data
In animal reproduction studies, no effects on embryo-fetal development were observed in pregnant rats given oral palonosetron HCl at doses up to 60 mg/kg/day (1,894 times the recommended human intravenous dose based on body surface area) or pregnant rabbits given oral doses up to 60 mg/kg/day (3,789 times the recommended human intravenous dose based on body surface area) during the period of organogenesis.
8.2 Lactation
Risk Summary
There are no data on the presence of palonosetron in human milk, the effects of palonosetron on the breastfed infant, or the effects of palonosetron on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Palonosetron Hydrochloride Injection and any potential adverse effect on the breastfed infant from palonosetron or from the underlying maternal condition.
8.4 Pediatric Use
Chemotherapy-Induced Nausea and Vomiting
Safety and effectiveness of Palonosetron Hydrochloride Injection have been established in pediatric patients aged 1 month to less than 17 years for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including HEC. Use is supported by a clinical trial where 165 pediatric patients aged 2 months to less than 17 years were randomized to receive a single dose of Palonosetron Hydrochloride Injection 20 mcg/kg (maximum 1.5 mg) administered as an intravenous infusion 30 minutes prior to the start of emetogenic chemotherapy [see Clinical Studies (14.2)]. While this study demonstrated that pediatric patients require a higher palonosetron dose than adults to prevent chemotherapy-induced nausea and vomiting, the safety profile is consistent with the established profile in adults [see Adverse Reactions (6.1)].
Safety and effectiveness of Palonosetron Hydrochloride Injection in neonates (less than 1 month of age) have not been established.
8.5 Geriatric Use
Of the 1,374 adult cancer patients in clinical studies of intravenously administered palonosetron HCl, 316 (23%) were 65 years and over, while 71 (5%) were at least 75 years and over. Of the 1,520 adult patients in clinical studies of intravenously administered palonosetron HCl, 73 (5%) were at least 65 years old [see Clinical Studies (14.1)]. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity in some older individuals cannot be ruled out. Population pharmacokinetics analysis did not reveal any differences in palonosetron pharmacokinetics between cancer patients 65 years of age and older compared to younger patients [see Clinical Pharmacology (12.3)]. No dose adjustment is required for geriatric patients.
10. OVERDOSAGE
There is no known antidote to palonosetron. Overdose should be managed with supportive care.
Dialysis studies have not been performed, however, due to the large volume of distribution, dialysis is unlikely to be an effective treatment for palonosetron overdose. A single intravenous dose of palonosetron (HCl) at 30 mg/kg (947 and 474 times the human dose for rats and mice, respectively, based on body surface area) was lethal to rats and mice. The major signs of toxicity were convulsions, gasping, pallor, cyanosis and collapse.
11. DESCRIPTION
Palonosetron Hydrochloride Injection contains palonosetron as palonosetron HCl, an antiemetic and antinauseant agent. It is a serotonin-3 (5-HT3) receptor antagonist with a strong binding affinity for this receptor. Chemically, palonosetron hydrochloride is: (3aS)-2-[(S)- 1-Azabicyclo [2.2.2]oct-3- yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1Hbenz[de] isoquinoline hydrochloride. Palonosetron hydrochloride exists as a single isomer and has the following structural formula:
Palonosetron Hydrochloride is a white to off-white crystalline powder. It is freely soluble in water, soluble in propylene glycol, and slightly soluble in ethanol and 2-propanol.
Palonosetron Hydrochloride Injection is a sterile, clear, colorless, non-pyrogenic, isotonic, buffered solution for intravenous administration. Palonosetron Hydrochloride Injection is available as a 5 mL single-dose prefilled syringe.
Each 5 mL syringe contains: 0.25 mg palonosetron (equivalent to 0.28 mg palonosetron HCl), 202.4 mg mannitol, 2.5 mg edetate disodium dihydrate, 18 mg trisodium citrate dihydrate, and 7 mg citric acid anhydrous in water for intravenous administration.
The pH of the solution in the 5 mL syringe is 4.5 to 5.5.
12. CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors.
Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors located on vagal afferents to initiate the vomiting reflex.
12.2 Pharmacodynamics
Cardiac Electrophysiology
The effect of intravenous palonosetron on blood pressure, heart rate, and ECG parameters including QTc were comparable to intravenous ondansetron and dolasetron in CINV clinical trials. In non-clinical studies palonosetron possesses the ability to block ion channels involved in ventricular de- and re-polarization and to prolong action potential duration.
At a dose of 9 times the maximum recommended adult dose, Palonosetron Hydrochloride Injection does not prolong the QT interval to any clinically relevant extent.
12.3 Pharmacokinetics
After intravenous dosing of palonosetron HCl in healthy subjects and cancer patients, an initial decline in palonosetron plasma concentrations is followed by a slow elimination from the body. Mean maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC0-∞) are generally dose-proportional over the dose range of 0.3 to 90 mcg/kg in healthy subjects and in cancer patients. Following a single intravenous dose of palonosetron HCl at 3 mcg/kg (or 0.21 mg/70 kg) to six cancer patients, mean (±SD) maximum plasma concentration was estimated to be 5,630 ± 5,480 ng/L and mean AUC was 35.8 ± 20.9 h•mcg/L.
Following intravenous administration of Palonosetron Hydrochloride Injection 0.25 mg once every other day for 3 doses in 11 cancer patients, the mean increase in plasma palonosetron concentration from Day 1 to Day 5 was 42±34%. Following intravenous administration of Palonosetron Hydrochloride Injection 0.25 mg once daily for 3 days in 12 healthy subjects, the mean (±SD) increase in plasma palonosetron concentration from Day 1 to Day 3 was 110±45%.
Distribution
Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg. Approximately 62% of palonosetron is bound to plasma proteins.
Elimination
After a single intravenous dose of 10 mcg/kg [14C]-palonosetron, approximately 80% of the dose was recovered within 144 hours in the urine with palonosetron representing approximately 40% of the administered dose. In healthy subjects, the total body clearance of palonosetron was 0.160 ± 0.035 L/h/kg and renal clearance was 0.067 ± 0.018 L/h/kg. Mean terminal elimination half-life is approximately 40 hours.
Metabolism
Palonosetron is eliminated by multiple routes with approximately 50% metabolized to form two primary metabolites: N-oxide-palonosetron and 6-S-hydroxy-palonosetron. These metabolites each have less than 1% of the 5-HT3 receptor antagonist activity of palonosetron. In vitro metabolism studies have suggested that CYP2D6 and to a lesser extent, CYP3A4 and CYP1A2 are involved in the metabolism of palonosetron. However, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolizers of CYP2D6 substrates.
Specific Populations
Pediatric Patients
Pharmacokinetic data was obtained from a subset of pediatric cancer patients that received 10 mcg/kg or 20 mcg/kg as a single intravenous dose of Palonosetron Hydrochloride Injection. When the dose was increased from 10 mcg/kg to 20 mcg/kg a dose-proportional increase in mean AUC was observed. Peak plasma concentrations (CT) reported at the end of the 15-minute infusion of 20 mcg/kg were highly variable in all age groups and tended to be lower in patients less than 6 years than in older patients as shown in Table 4. The median half-life was 30 hours in overall age groups and ranged from about 20 to 30 hours across age groups after administration of 20 mcg/kg.
The total body clearance (L/h/kg) in patients 12 to 17 years old was similar to that in healthy adults. There are no apparent differences in volume of distribution when expressed as L/kg.
|
a Geometric Mean (CV) except for t1/2 which is median values |
||||
|
b CT is the plasma palonosetron concentration at the end of the 15-minute infusion |
||||
|
c Clearance and Vss calculated from 10 and 20 mcg/kg and are weight adjusted |
||||
|
PK Parametera | Pediatric Age Group | |||
| Less than 2 years | 2 years to less than
6 years | 6 years to less than 12 years | 12 years to less than
17 years |
|
| N=12 | N=42 | N=38 | N=44 | |
| CTb, ng/L | 9025 (197) | 9414 (252) | 16275 (203) | 11831 (176) |
| N=5 | N=7 | N=10 | ||
| AUC0-∞, h·mcg/L | 103.5 (40.4) | 98.7 (47.7) | 124.5 (19.1) | |
| N=6 | N=14 | N=13 | N=19 | |
| Clearancec, L/h/kg | 0.31 (34.7) | 0.23 (51.3) | 0.19 (46.8) | 0.16 (27.8) |
| Vssc, L/kg | 6.08 (36.5) | 5.29 (57.8) | 6.26 (40.0) | 6.20 (29.0) |
Racial or Ethnic Groups
The pharmacokinetics of palonosetron were characterized in 24 healthy Japanese subjects over an intravenous dose range of 3 to 90 mcg/kg. Total body clearance was 25% higher in Japanese subjects compared to Whites, however, this increase is not considered to be clinically meaningful.
Patients with Renal Impairment
Mild to moderate renal impairment does not significantly affect palonosetron pharmacokinetic parameters. Total systemic exposure increased by approximately 28% in patients with severe renal impairment relative to healthy subjects. This increase is not considered clinically meaningful.
Drug Interaction Studies
In vitro studies indicated that palonosetron is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4/5 (CYP2C19 was not investigated) nor does it induce the activity of CYP1A2, CYP2D6, or CYP3A4/5. Therefore, the potential for clinically significant drug interactions with palonosetron appears to be low.
Dexamethasone
Coadministration of 0.25 mg Palonosetron Hydrochloride Injection and 20 mg dexamethasone administered intravenously in healthy subjects revealed no pharmacokinetic drug-interactions between palonosetron and dexamethasone.
Oral Aprepitant
In an interaction study in healthy subjects where a single 0.25 mg intravenous dose of Palonosetron Hydrochloride Injection was administered on day 1 and oral aprepitant for 3 days (125 mg/80 mg/80 mg), the pharmacokinetics of palonosetron were not significantly altered (AUC: no change, Cmax: 15% increase).
13. NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
In a 104-week carcinogenicity study in CD-1 mice, animals were treated with oral doses of palonosetron HCl at 10, 30 and 60 mg/kg/day. Treatment with palonosetron was not tumorigenic. The highest tested dose produced a systemic exposure to palonosetron (Plasma AUC) of about 150 to 289 times the human exposure (AUC= 29.8 h•mcg/L) at the recommended intravenous dose of 0.25 mg. In a 104-week carcinogenicity study in Sprague-Dawley rats, male and female rats were treated with oral doses of 15, 30 and 60 mg/kg/day and 15, 45 and 90 mg/kg/day, respectively. The highest doses produced a systemic exposure to palonosetron (Plasma AUC) of 137 and 308 times the human exposure at the recommended dose. Treatment with palonosetron produced increased incidences of adrenal benign pheochromocytoma and combined benign and malignant pheochromocytoma, increased incidences of pancreatic Islet cell adenoma and combined adenoma and carcinoma and pituitary adenoma in male rats. In female rats, it produced hepatocellular adenoma and carcinoma and increased the incidences of thyroid C-cell adenoma and combined adenoma and carcinoma.
Palonosetron was not genotoxic in the Ames test, the Chinese hamster ovarian cell (CHO/HGPRT) forward mutation test, the ex vivo hepatocyte unscheduled DNA synthesis (UDS) test or the mouse micronucleus test. It was, however, positive for clastogenic effects in the Chinese hamster ovarian (CHO) cell chromosomal aberration test.
Palonosetron HCl at oral doses up to 60 mg/kg/day (about 1,894 times the recommended human intravenous dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.
14. CLINICAL STUDIES
14.1 Prevention of Nausea and Vomiting Associated with MEC and HEC in Adults
Efficacy of a single intravenous dose of Palonosetron Hydrochloride Injection in preventing acute and delayed nausea and vomiting associated with MEC or HEC were studied in 4 trials. In these double-blind studies, complete response rates (no emetic episodes and no rescue medication) and other efficacy parameters were assessed through at least 120 hours after administration of chemotherapy.
The safety and efficacy of Palonosetron Hydrochloride Injection in repeated courses of chemotherapy was also assessed.
Moderately Emetogenic Chemotherapy
Two double-blind trials (Study 1 and Study 2) involving 1,132 patients compared a single dose of Palonosetron Hydrochloride Injection with either a single-dose of ondansetron (Study 1) or dolasetron (Study 2) given 30 minutes prior to MEC, including carboplatin, cisplatin ≤ 50 mg/m2, cyclophosphamide < 1,500 mg/m2, doxorubicin > 25 mg/m2, epirubicin, irinotecan, and methotrexate > 250 mg/m2. Concomitant corticosteroids were not administered prophylactically in Study 1 and were only used by 4 to 6% of patients in Study 2. The majority of patients in these studies were women (77%), White (65%) and naïve to previous chemotherapy (54%). The mean age was 55 years.
Highly Emetogenic Chemotherapy
A double-blind, dose-ranging trial evaluated the efficacy of a single intravenous dose of Palonosetron Hydrochloride Injection from 0.3 to 90 mcg/kg (equivalent to < 0.1 mg to 6 mg fixed dose) in 161 chemotherapy-naïve adult cancer patients receiving HEC, either cisplatin ≥ 70 mg/m2 or cyclophosphamide > 1,100 mg/m2. Concomitant corticosteroids were not administered prophylactically. Analysis of data from this trial indicates that 0.25 mg is the lowest effective dose in preventing acute nausea and vomiting associated with HEC.
A double-blind trial involving 667 patients compared a single intravenous dose of Palonosetron Hydrochloride Injection with a single intravenous dose of ondansetron (Study 3) given 30 minutes prior to HEC, including cisplatin ≥ 60 mg/m2, cyclophosphamide > 1,500 mg/m2, and dacarbazine. Corticosteroids were co-administered prophylactically before chemotherapy in 67% of patients. Of the 667 patients, 51% were women, 60% White, and 59% naïve to previous chemotherapy. The mean age was 52 years.
Efficacy Results
Studies 1, 2 and 3 show that Palonosetron Hydrochloride Injection was effective in the prevention of nausea and vomiting associated with initial and repeat courses of MEC and HEC in the acute phase (0 to 24 hours) [Table 5]. Clinical superiority over other 5-HT3 receptor antagonists has not been adequately demonstrated in the acute phase. In Study 3, efficacy was greater when prophylactic corticosteroids were administered concomitantly.
Studies 1 and 2 show that Palonosetron Hydrochloride Injection was effective in the prevention of nausea and vomiting associated with initial and repeat course of MEC in the delayed phase (24 to 120 hours) [Table 6] and overall phase (0 to 120 hours) [Table 7].
14.2 Prevention of Nausea and Vomiting Associated with Emetogenic Chemotherapy, Including HEC in Pediatric Patients
One double-blind, active-controlled clinical trial was conducted in pediatric cancer patients. The total population (N = 327) had a mean age of 8.3 years (range 2 months to 16.9 years) and were 53% male; and 96% white. Patients were randomized and received a 20 mcg/kg (maximum 1.5 mg) intravenous infusion of Palonosetron Hydrochloride Injection 30 minutes prior to the start of emetogenic chemotherapy (followed by placebo infusions 4 and 8 hours after the dose of Palonosetron Hydrochloride injection) or 0.15 mg/kg of intravenous ondansetron 30 minutes prior to the start of emetogenic chemotherapy (followed by ondansetron 0.15 mg/kg infusions 4 and 8 hours after the first dose of ondansetron, with a maximum total dose of 32 mg). Emetogenic chemotherapies administered included doxorubicin, cyclophosphamide (< 1,500 mg/m2), ifosfamide, cisplatin, dactinomycin, carboplatin, and daunorubicin. Adjuvant corticosteroids, including dexamethasone, were administered with chemotherapy in 55% of patients.
Complete Response in the acute phase of the first cycle of chemotherapy was defined as no vomiting, no retching, and no rescue medication in the first 24 hours after starting chemotherapy. Efficacy was based on demonstrating non-inferiority of intravenous Palonosetron Hydrochloride injection compared to intravenous ondansetron. Non-inferiority criteria were met if the lower bound of the 97.5% confidence interval for the difference in Complete Response rates of intravenous Palonosetron Hydrochloride injection minus intravenous ondansetron was larger than -15%. The non-inferiority margin was 15%.
Efficacy Results
As shown in Table 8, intravenous Palonosetron Hydrochloride Injection 20 mcg/kg (maximum 1.5 mg) demonstrated non-inferiority to the active comparator during the 0 to 24-hour time interval.
|
a To adjust for multiplicity of treatment groups, a lower-bound of a 97.5% confidence interval was used to compare to -15%, the negative value of the non-inferiority margin. |
||
| Palonosetron Hydrochloride Injection 20 mcg/kg intravenously (N=165) | Ondansetron 0.15 mg/kg for 3 intravenous doses (N=162) | Difference [97.5% Confidence Interval]a: Palonosetron Hydrochloride Injection minus intravenous Ondansetron Comparator |
| 59.4% | 58.6% | 0.36% [-11.7%, 12.4%] |
In patients that received Palonosetron Hydrochloride Injection at a lower dose than the recommended dose of 20 mcg/kg, non-inferiority criteria were not met.
16. HOW SUPPLIED/STORAGE AND HANDLING
17. PATIENT COUNSELING INFORMATION
Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information).
Hypersensitivity Reactions
Advise patients that hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported in patients with or without known hypersensitivity to other 5-HT3 receptor antagonists. Advise patients to seek immediate medical attention if any signs or symptoms of a hypersensitivity reaction occur with administration of Palonosetron Hydrochloride Injection [see Warnings and Precautions (5.1)].
Serotonin Syndrome
Advise patients of the possibility of serotonin syndrome, especially with concomitant use of Palonosetron Hydrochloride injection and another serotonergic agent such as medications to treat depression and migraines. Advise patients to seek immediate medical attention if the following symptoms occur: changes in mental status, autonomic instability, neuromuscular symptoms with or without gastrointestinal symptoms [see Warnings and Precautions (5.2)].
Lake Zurich, IL 60047
Made in Austria
www.fresenius-kabi.com/us
451400B
SPL UNCLASSIFIED SECTION
PRINCIPAL DISPLAY PANEL
PRINCIPAL DISPLAY PANEL
PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Palonosetron Hydrochloride 0.25 mg Single-Dose Prefilled Syringe Individual Carton Panel
NDC 63323-673-21
Palonosetron Hydrochloride Injection
0.25 mg* per 5 mL
(0.05 mg* per mL)
For Intravenous Injection Only.
Discard Unused Portion. Rx only
1x 5 mL Single-Dose Syringe
PRINCIPAL DISPLAY PANEL
INGREDIENTS AND APPEARANCE
| PALONOSETRON
palonosetron injection, solution |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
| Labeler - Fresenius Kabi USA, LLC (608775388) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| Fresenius Kabi Austria | 300206604 | ANALYSIS(63323-673) , MANUFACTURE(63323-673) , PACK(63323-673) | |